A Phase 3 interventional study of Rituximab and CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) in Non-Hodgkin's Lymphoma, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-15.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 11th largest by enrollment of the 171 interventional ones that give a count, is one of 7 that started in 2008, is one of 29 in phase 3, and was the 91st registered.
2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:
Paolo Caimi, MD · Sites in United States
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
University of Cologne · Sites in Germany
Ages 18–99
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
M.D. Anderson Cancer Center · Sites in United States
Ages 15–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
178 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 112 · Phase 3 30 · Phase 4 5
First in 1995; this study’s year is marked. 7 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 451 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 38 across the 171 interventional studies. Of the 152 that completed or were terminated, 80 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 178 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche: 1 open now, 6 under way, 1 of them phase 3. Of 47 finished, 22 (47%) have results posted.
Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one is the 9th largest by enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2008, is one of 11 in phase 3, and was the 10th registered.
Hoffmann-La Roche’s Lymphoma, Non-Hodgkin studies by the year they started, since 1997.
4 of the studies testing rituximab in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05583071University of CologneMethotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | 2027-02 |
| NCT01829958Memorial Sloan Kettering Cancer CenterComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | 2027-04 |
| NCT02727803M.D. Anderson Cancer CenterPersonalized NK Cell Therapy in CBT | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, from their registry updates:
Among Hoffmann-La Roche’s 54 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
This was a prospective, open-label, Phase III, multicenter, single-arm trial designed to assess the safety, pharmacokinetics, and pharmacodynamics of an alternative dosing rate of rituximab in previously untreated patients with diffuse large B-cell lymphoma (DLBCL) and follicular non-Hodgkin lymphoma (NHL).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
* cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction, unstable angina), (NYHA) Classification Grade II or greater congestive heart failure, a ventricular arrhythmia requiring medication within 1 year prior to Day 1, or NYHA Grade II or greater peripheral vascular disease on Day 1 (first day of treatment)
Patients who meet any of the following criteria will be excluded from further study participation after Cycle 1:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m\^2 administered by intravenous (IV) infusion on Day 1 of each cycle.
Drug: Rituximab · Drug: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) · Drug: CVP (cyclophosphamide, vincristine, prednisone) · Drug: Analgesic/antipyretic and antihistamine drugs
During Cycle 1 rituximab was administered at an initial rate of 50 mg/hour. In the absence of infusion toxicity during Cycle 1, the infusion rate was escalated by 50 mg/h increments every 30 minutes to a maximum rate of 400 mg/hour. In case of infusion-related reactions, the infusion was interrupted or the infusion rate reduced. In case of Grade 3/4 infusion reactions, the rituximab infusion was discontinued and medical treatment provided. If the rituximab infusion in Cycle 1 was tolerated without a serious adverse event (AE) or Grade 3/4 infusion-related AE, as judged by the investigator, infusions in Cycle 2 onwards were administered as follows: 20% of the total dose was given over 30 minutes and the remaining 80% of the dose was given over the next 60 minutes, for a total infusion time of 90 minutes. Commercial preparations of rituximab were used.
Commercial preparations of CHOP were used. Prednisone was administered prior to rituximab infusion.
Commercial preparations of CVP were used. Prednisone was administered prior to rituximab infusion.
An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.
Percentage of Patients Who Developed Grade 3 or 4 Infusion-related Reactions (IRR) Resulting From Faster Infusion of Rituximab During Days 1 and 2 of Cycle 2
The percentage of patients who developed Grade 3 or 4 IRRs resulting from faster infusion of rituximab at Cycle 2 was assessed in patients who had previously received rituximab at the standard infusion rate without experiencing a Grade 3 or 4 IRR at Cycle 1. IRRs were a predefined list of Medical Dictionary for Regulatory Activities (MedDRA) terms for infusion-related adverse events occurring on the day of and/or the day after rituximab infusion. The list of IRR terms was compiled based on IRRs observed in the present and previous studies in which rituximab was infused at the standard rate.
Time frame: Days 1 and 2 of Cycle 2
Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 1
Time frame: Cycle 1
Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 2 Through Cycle 6 or 8 (End of Study)
Time frame: Cycle 2 through Cycle 6 or 8 (end of study)
Duration of Rituximab Infusion Including Dose Interruption Times
The median duration of the rituximab infusion on Day 1 of each cycle, including the duration of dose interruptions, is reported.
Time frame: Day 1 of each of Cycles 1 to 6 or 8
Maximum Serum Concentration (Cmax) of Rituximab Post-dose at the First Alternative Dosing Rate (Cycle 2) and the Last Cycle (Either Cycle 6 or 8)
Serum samples for rituximab pharmacokinetic analysis were taken pre-dose (within 15 minutes before rituximab infusion) and post-dose (within 15 minutes after the end of the rituximab infusion) after the first faster infusion (Cycle 2) and after the last infusion (either Cycle 6 or 8). An enzyme-linked immunosorbent assay (ELISA) was used to measure rituximab levels in the serum samples.
Time frame: Day 1 of Cycles 2 and either 6 or 8 (last cycle)
Percentage of Patients Who Had Undetectable Levels of CD19+ Lymphocytes at Cycle 2 and Either Cycle 6 or 8 (Last Cycle)
Serum samples for measurement of CD19+ lymphocytes were taken pre-dose (within 15 minutes before rituximab infusion). CD19+ lymphocyte counts were measured by flow cytometry using a fluorescent-activated cell sorter (FACS).
Time frame: Day 1 of Cycle 2 and either Cycle 6 or 8 (last cycle)
| Milestone | Rituximab 375 mg/m^2 |
|---|---|
| Started | 451 |
| Completed | 425 |
| Not completed | 26 |
| Withdrew: Physician decision to withdraw patient | 1 |
| Withdrew: Subject decision to withdraw | 8 |
| Withdrew: Various reasons | 17 |
| Milestone | Rituximab 375 mg/m^2 |
|---|---|
| Started | 425 |
| Completed | 372 |
| Not completed | 53 |
| Withdrew: Adverse event | 8 |
| Withdrew: Death | 5 |
| Withdrew: Eligibility criteria for cycle 2 not met | 11 |
| Withdrew: Physician decision to withdraw patient | 7 |
| Withdrew: Subject decision to withdraw | 9 |
| Withdrew: Various reasons | 13 |
| Milestone | Rituximab 375 mg/m^2 |
|---|---|
| Started | 372 |
| Completed | 304 |
| Not completed | 68 |
| Withdrew: Adverse event | 12 |
| Withdrew: Death | 6 |
| Withdrew: Disease progression | 3 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Physician decision to withdraw patient | 13 |
| Withdrew: Subject decision to withdraw | 6 |
| Withdrew: Various reasons | 25 |
The percentage of patients who developed Grade 3 or 4 IRRs resulting from faster infusion of rituximab at Cycle 2 was assessed in patients who had previously received rituximab at the standard infusion rate without experiencing a Grade 3 or 4 IRR at Cycle 1. IRRs were a predefined list of Medical Dictionary for Regulatory Activities (MedDRA) terms for infusion-related adverse events occurring on the day of and/or the day after rituximab infusion. The list of IRR terms was compiled based on IRRs observed in the present and previous studies in which rituximab was infused at the standard rate.
| Percentage of participants | Rituximab 375 mg/m^2 |
|---|---|
| Percentage of Patients Who Developed Grade 3 or 4 Infusion-related Reactions (IRR) Resulting From Faster Infusion of Rituximab During Days 1 and 2 of Cycle 2 | 1.1 (0.3 to 2.8) |
| Percentage of participants | Rituximab 375 mg/m^2 |
|---|---|
| Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 1 | 91.8 |
| Percentage of participants | Rituximab 375 mg/m^2 |
|---|---|
| Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 2 Through Cycle 6 or 8 (End of Study) | 98.6 |
The median duration of the rituximab infusion on Day 1 of each cycle, including the duration of dose interruptions, is reported.
| Minutes | Rituximab 375 mg/m^2 |
|---|---|
| Cycle 1 (n=362) | 245 (225 to 273) |
| Cycle 2 (n=363) | 91 (90 to 98) |
| Cycle 3 (n=344) | 91 (90 to 98) |
| Cycle 4 (n=329) | 91 (90 to 96) |
| Cycle 5 (n=312) | 91 (90 to 95) |
| Cycle 6 (n=303) | 91 (90 to 96) |
| Cycle 7 (n=59) | 91 (90 to 95) |
| Cycle 8 (n=59) | 91 (90 to 95) |
Serum samples for rituximab pharmacokinetic analysis were taken pre-dose (within 15 minutes before rituximab infusion) and post-dose (within 15 minutes after the end of the rituximab infusion) after the first faster infusion (Cycle 2) and after the last infusion (either Cycle 6 or 8). An enzyme-linked immunosorbent assay (ELISA) was used to measure rituximab levels in the serum samples.
| µg/mL | Rituximab 375 mg/m^2 |
|---|---|
| Cycle 2 (n=335) | 228.0 ± 63.7 |
| Cycle 6 (n=238) | 275.0 ± 71.5 |
| Cycle 8 (n=36) | 299.0 ± 90.6 |
Serum samples for measurement of CD19+ lymphocytes were taken pre-dose (within 15 minutes before rituximab infusion). CD19+ lymphocyte counts were measured by flow cytometry using a fluorescent-activated cell sorter (FACS).
| Percentage of participants | Rituximab 375 mg/m^2 |
|---|---|
| Cycle 2 (n=338) | 50.5 ± 24 |
| Cycle 6 (n=240) | 68.3 ± 4 |
| Cycle 8 (n=32) | 87.5 ± 0 |
Collected over Adverse events and serious adverse events were recorded from the start of study treatment until 30 days following the last administration of study treatment or at study discontinuation/early termination, whichever occurred earlier.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab 375 mg/m^2 | — | 107/425 (25.2%) | 421/425 (99.1%) |
| Event | Rituximab 375 mg/m^2 |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 33/425 |
| DehydrationMetabolism and nutrition disorders | 12/425 |
| NeutropeniaBlood and lymphatic system disorders | 10/425 |
| PancytopeniaBlood and lymphatic system disorders | 7/425 |
| PneumoniaInfections and infestations | 7/425 |
| Abdominal painGastrointestinal disorders | 6/425 |
| AnaemiaBlood and lymphatic system disorders | 5/425 |
| SepsisInfections and infestations | 5/425 |
| Cardiac failure congestiveCardiac disorders | 3/425 |
| Atrial fibrillationCardiac disorders | 3/425 |
| Event | Rituximab 375 mg/m^2 |
|---|---|
| FatigueGeneral disorders | 227/425 |
| NauseaGastrointestinal disorders | 202/425 |
| AlopeciaSkin and subcutaneous tissue disorders | 169/425 |
| ConstipationGastrointestinal disorders | 142/425 |
| NeutropeniaBlood and lymphatic system disorders | 135/425 |
| AnaemiaBlood and lymphatic system disorders | 100/425 |
| InsomniaPsychiatric disorders | 100/425 |
| DiarrhoeaGastrointestinal disorders | 99/425 |
| Neuropathy peripheralNervous system disorders | 99/425 |
| HeadacheNervous system disorders | 75/425 |
| Age, Continuous(years) | Rituximab 375 mg/m^2 |
|---|---|
| Mean | 62.7 ± 13.4 |
| Sex: Female, Male(Participants) | Rituximab 375 mg/m^2 |
|---|---|
| Female | 191 |
| Male | 234 |
No study locations are listed for this record.
The record gives a start of Jul 2008, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab